Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab for Prevention of Polyps and Tumors in Lynch Syndrome
NCT04711434Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in Lynch syndrome (LS), sponsored by Sun Yat-sen University. Started Nov 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT04711434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711434.